DICER1 Syndrome via the DICER1 Gene
Use
This test is for individuals with relevant features who have a clinical or suspected diagnosis of DICER1 syndrome, as well as those with a family history of pleuropulmonary blastoma, cystic nephroma, or ovarian Sertoli-Leydig tumors. It also targets children under 7 years of age with lung cysts or pneumothorax, and females under 40 years of age with ovarian sex cord-stromal tumors.
Special Instructions
Testing is part of PreventionGenetics' offerings and follows CAP and CLIA regulations. However, tests have not been cleared or approved by the US Food and Drug Administration. The facility is located in Marshfield, Wisconsin, and is a subsidiary of Exact Sciences Corp.
Limitations
This genetic test has not been cleared or approved by the FDA, which may introduce certain limitations in terms of clinical use. Interpretation directly correlates with the quality of clinical information provided, necessitating comprehensive clinical records attachment.
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided